During a live event, Carol Ann Huff, MD, and participants discussed real-world evidence and personal experiences with talquetamab in relapsed/refractory multiple myeloma.
Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...
Naomi Haas, MD, from the Hospital at the University of Pennsylvania, explains that most trials regarding neoadjuvant therapy ...
Dr Danny Nguyen discusses the shift of clinical trials to community settings, the impact of AI in oncology, and the latest ...
Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...
The FDA has granted Fast Track designation to the investigational antibody-drug conjugate (ADC) SIM0505 for the treatment of women with platinum-resistant ovarian cancer. The designation adds SIM0505 ...
The FDA has granted Orphan Drug Designation to tovecimig (CTX-009) for the treatment of patients with biliary tract cancer ...
The FDA has granted fast track and rolling review status to Celltrion’s CT-P71, a Nectin-4 targeting ADC for treating ...
FDA grants orphan drug designation to rhenium (186Re) obisbemeda for pediatric glioma and ependymoma, supported by the phase ...
Dr. Costa addresses the primary clinician concern regarding BCMA-directed T-cell engagers: infection risk. Early trials ...
A newly FDA-approved therapy is offering a different approach for patients with platinum-resistant ovarian cancer—an area ...
Dr Komrokji explains how the IPSS-M improves prognostic precision in MDS but cautions that upstaging alone should not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results